The medical term for dust allergy is allergic rhinitis, most commonly caused by house dust mite (HDM) allergy in the UK. House dust mites produce microscopic faecal particles and body fragments that trigger an IgE-mediated immune response in sensitised individuals, causing persistent nasal, eye, and airway symptoms. Unlike seasonal hay fever, dust mite allergy tends to cause year-round (perennial) symptoms, often worsening in bedrooms and poorly ventilated spaces. This article explains the clinical terminology, symptoms, diagnosis, NHS-recommended treatments, and practical management strategies to help you understand and address this common allergic condition.

The Medical Term for Dust Allergy Explained

The medical term for dust allergy is allergic rhinitis, most commonly attributed to house dust mite allergy, where IgE antibodies trigger histamine release from mast cells upon exposure to mite faecal particles and body fragments.

The medical term for a dust allergy is allergic rhinitis, though reactions triggered by household dust are most commonly attributed to house dust mite (HDM) allergy. It is worth noting that 'dust allergy' may also involve other indoor allergens — such as pet dander, mould spores, or cockroach particles — so a clinical assessment is important to identify the specific trigger.

House dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae) are microscopic arachnids that thrive in warm, humid domestic environments. It is not the mites themselves but their faecal particles and body fragments that act as allergens, triggering an immune response in sensitised individuals.

When a sensitised person inhales these allergen particles, the immune system mistakenly identifies them as harmful. This triggers the production of immunoglobulin E (IgE) antibodies, which bind to mast cells in the nasal lining and airways. Upon re-exposure, these mast cells release histamine and other inflammatory mediators, producing the characteristic symptoms of allergic rhinitis.

Allergic rhinitis is classified as either seasonal (triggered by pollen) or perennial (year-round, typically caused by indoor allergens such as house dust mites, pet dander, or mould). Clinicians also use the ARIA (Allergic Rhinitis and its Impact on Asthma) classification, which describes symptoms as intermittent or persistent, and as mild or moderate–severe — a framework that helps guide treatment decisions. House dust mite allergy is one of the most common causes of perennial allergic rhinitis in the UK. The condition is closely associated with asthma and allergic conjunctivitis, and frequently occurs alongside eczema as part of the atopic triad.

Understanding the correct medical terminology helps patients communicate more effectively with healthcare professionals and access appropriate guidance from sources such as the NHS, NICE, BSACI, and Allergy UK.

Symptoms of Allergic Rhinitis and House Dust Mite Allergy

Symptoms include persistent nasal congestion, runny nose, sneezing, itchy eyes, and postnasal drip, typically worse in the morning and at night due to high allergen concentrations in bedding.

The symptoms of house dust mite allergy and allergic rhinitis can significantly affect quality of life, particularly as they tend to persist throughout the year rather than being confined to a specific season. The most commonly reported symptoms include:

• Persistent nasal congestion or blockage

• Runny nose (rhinorrhoea) with clear, watery discharge

• Sneezing, often in repeated bouts

• Itching of the nose, eyes, throat, or roof of the mouth

• Watery, red, or swollen eyes (allergic conjunctivitis)

• Postnasal drip, which may cause a chronic cough or throat irritation

Symptoms are frequently worse in the morning and at night, as dust mite concentrations are highest in bedding and mattresses. Many individuals notice that symptoms worsen when making beds, vacuuming, or spending prolonged periods in poorly ventilated rooms.

In individuals with co-existing asthma, exposure to house dust mite allergens can also trigger or worsen wheeze, chest tightness, and breathlessness. Poorly controlled allergic rhinitis can make asthma harder to manage, as the upper and lower airways are closely connected — a concept supported by the 'one airway, one disease' model described in the ARIA guideline and endorsed by international respiratory bodies including GINA.

Chronic symptoms may also contribute to sleep disturbance, fatigue, difficulty concentrating, and reduced productivity, particularly in children and working-age adults. If symptoms are persistent and interfering with daily life, it is advisable to seek assessment from a GP rather than relying solely on over-the-counter remedies. See the final section for guidance on when to seek further medical advice.

Not sure if this is normal? Chat with one of our pharmacists →

How Dust Allergies Are Diagnosed in the UK

Diagnosis begins with a detailed clinical history from a GP or allergy specialist; skin prick testing or specific IgE blood testing confirms sensitisation when needed, particularly before immunotherapy.

Diagnosis of house dust mite allergy in the UK typically begins with a detailed clinical history taken by a GP or allergy specialist. The clinician will ask about the pattern, timing, and triggers of symptoms, as well as any personal or family history of atopic conditions such as asthma, eczema, or hay fever. This history is often sufficient to make a working diagnosis of perennial allergic rhinitis.

Where confirmation is needed — particularly before initiating allergen immunotherapy or in cases of diagnostic uncertainty — further testing may be arranged. The two principal methods used in the UK are:

• Skin prick testing (SPT): A small amount of standardised allergen extract is introduced into the skin via a lancet. A positive result produces a wheal (raised bump) at the test site within 15–20 minutes, indicating IgE-mediated sensitisation. SPT should be performed by trained clinicians in a setting with appropriate resuscitation facilities, given the small risk of a systemic reaction.

• Specific IgE blood testing (previously known as RAST): A blood sample is analysed for IgE antibodies specific to house dust mite allergens. This is particularly useful when SPT is not feasible — for example, in patients with extensive eczema or those taking antihistamines that cannot be stopped.

It is important to note that a positive allergy test alone does not confirm clinical allergy — results must always be interpreted alongside the patient's symptoms and history, and testing should be targeted to the allergens most likely to be relevant. NICE CKS (Allergic rhinitis) and the British Society for Allergy and Clinical Immunology (BSACI) recommend that allergy testing be performed and interpreted by trained clinicians.

In children, diagnosis follows similar principles, though referral to a paediatric allergy service may be appropriate for complex or severe presentations.

NHS-Recommended Treatments for Allergic Rhinitis

NICE CKS recommends a stepwise approach starting with intranasal corticosteroid sprays and non-sedating antihistamines; allergen immunotherapy is a specialist option for moderate-to-severe perennial disease unresponsive to pharmacotherapy.

NICE CKS (Allergic rhinitis) and NHS recommendations outline a stepwise approach to managing allergic rhinitis, beginning with allergen avoidance and progressing to pharmacological treatment as required. The ARIA classification of symptom severity and pattern should guide treatment choice.

Saline nasal irrigation (e.g., using a saline rinse or spray) is a simple, low-risk adjunct that can help clear nasal passages and reduce allergen load; it may be used alongside other treatments.

First-line pharmacological options include:

• Intranasal corticosteroid sprays (e.g., beclometasone, fluticasone, mometasone): These are considered the most effective treatment for persistent allergic rhinitis. They reduce nasal inflammation and are available both on prescription and over the counter. Regular, consistent use is essential for maximum benefit.

• Non-sedating oral antihistamines (e.g., cetirizine, loratadine, fexofenadine): These are effective for sneezing, itching, and runny nose but are less effective for nasal congestion. They are widely available without prescription.

• Antihistamine nasal sprays (e.g., azelastine): These offer a faster onset of action than oral antihistamines and may be used as an alternative or adjunct.

For patients with moderate-to-severe symptoms not adequately controlled by monotherapy, a combination intranasal spray containing azelastine and fluticasone is a licensed option that may provide greater relief than either agent alone.

For prominent watery rhinorrhoea that does not respond to the above treatments, intranasal ipratropium bromide may be considered on specialist advice.

For patients with both nasal and eye symptoms, antihistamine eye drops (e.g., ketotifen, olopatadine) or sodium cromoglicate eye drops (a mast cell stabiliser, not an antihistamine) may provide additional relief.

Topical nasal decongestants (e.g., xylometazoline) may offer short-term relief of congestion but should be used for a maximum of 3–7 days only, as prolonged use can cause rebound congestion (rhinitis medicamentosa).

Montelukast is not routinely recommended as a first-line treatment for allergic rhinitis in isolation. If it is considered — for example, in patients with coexisting asthma who cannot tolerate other therapies — patients and carers should be counselled about the MHRA-reported risk of neuropsychiatric reactions (including sleep disturbances, mood changes, and suicidal thoughts). Further information is available in the MHRA Drug Safety Update.

In cases of severe or refractory symptoms, a short course of oral corticosteroids may occasionally be prescribed, though this is generally reserved for exceptional circumstances due to systemic side-effect risks.

For patients with moderate-to-severe perennial allergic rhinitis who do not respond adequately to standard pharmacotherapy, allergen immunotherapy (desensitisation) may be considered by a specialist. This involves administering gradually increasing doses of allergen — either via subcutaneous injection (SCIT) or sublingual tablets or drops (SLIT) — to induce long-term immune tolerance. Immunotherapy is specialist-initiated, requires confirmed IgE-mediated sensitisation, and is generally licensed for adolescents and adults (specific age ranges and indications vary by product — refer to the relevant Summary of Product Characteristics on the MHRA/eMC website). It is contraindicated in severe or uncontrolled asthma. Sublingual house dust mite immunotherapy tablets are available through NHS specialist allergy services where clinically appropriate.

Patients should report any suspected side effects from medicines — including those used for allergic rhinitis — to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Managing Dust Mite Exposure at Home

Allergen-impermeable mattress and pillow covers combined with weekly bedding washes at 60°C are the most evidence-supported measures; a sustained, combined approach is more effective than any single intervention.

Reducing exposure to house dust mite allergens is recommended alongside medical treatment by both NICE CKS and BSACI. However, it is important to set realistic expectations: evidence from Cochrane reviews and clinical guidelines suggests that single measures have limited impact on symptoms, and that a combined, sustained approach is more likely to achieve a meaningful reduction in allergen load. Environmental control measures should complement — not replace — appropriate medical treatment.

Bedroom measures are particularly important, as people spend approximately a third of their lives in bed:

• Encase mattresses, pillows, and duvets in allergen-impermeable covers (fine-weave or microporous fabric) — this is the most evidence-supported single measure

• Wash bedding weekly at 60°C or above to kill dust mites and remove allergen

• If allergen-impermeable covers are used, the type of pillow or duvet fill is less critical; however, if covers are not used, synthetic fills may be easier to launder regularly

• Avoid soft toys in beds; if unavoidable, freeze them overnight to kill mites, then wash at 60°C to remove allergen particles

General household measures include:

• Vacuum regularly using a cleaner fitted with a HEPA filter to trap fine allergen particles

• Damp-dust hard surfaces rather than dry dusting, which disperses allergens into the air

• Reduce indoor humidity to below 50% using adequate ventilation or a dehumidifier, as dust mites require humidity to survive

• Replace carpets with hard flooring where possible, particularly in bedrooms

• Minimise soft furnishings such as heavy curtains and upholstered furniture

Air purifiers with HEPA filters may offer modest benefit in reducing airborne allergen particles, but evidence for their standalone effectiveness is limited. As with all environmental measures, they are most useful as part of a broader, consistent strategy combined with appropriate medical treatment.

When to Seek Further Medical Advice

Consult a GP if symptoms are persistent, severe, or uncontrolled after 2–4 weeks of over-the-counter treatment; unilateral nasal obstruction, unexplained nosebleeds, or facial swelling require prompt assessment to exclude serious conditions.

Many people with mild allergic rhinitis manage their symptoms effectively with over-the-counter antihistamines and nasal sprays. However, there are several circumstances in which it is important to consult a GP or seek specialist referral.

Contact your GP if:

• Symptoms are persistent, severe, or significantly affecting sleep, work, school, or daily activities

• Over-the-counter treatments have not provided adequate relief after 2–4 weeks of consistent use

• You develop new or worsening asthma symptoms, such as wheeze, breathlessness, or nocturnal cough

• There is uncertainty about the diagnosis, particularly if symptoms are atypical or do not follow the expected pattern

• You are considering allergen immunotherapy and wish to discuss suitability

• Symptoms occur in a young child, particularly if associated with recurrent ear infections, sleep-disordered breathing, or poor growth

Your GP should also be contacted promptly — or an urgent referral arranged — if you notice any of the following features that may indicate a different or more serious condition:

• Unilateral (one-sided) nasal obstruction or discharge

• Recurrent or unexplained nosebleeds

• Facial pain or swelling, or symptoms suggesting sinusitis that does not resolve

• Nasal polyps or visible nasal masses

• Orbital or neurological symptoms (e.g., visual changes, severe headache)

These features may warrant referral to ENT (ear, nose and throat) services for further assessment, in line with NHS referral pathways.

Call 999 or go to your nearest A&E immediately if you experience:

• Severe breathlessness or wheeze that does not respond to a reliever inhaler

• Signs of anaphylaxis — though rare with inhalant allergens, these include throat swelling, difficulty breathing, dizziness, or collapse

GPs may refer patients to an NHS allergy clinic, immunology service, or ENT department for specialist assessment, allergy testing, or consideration of immunotherapy. Waiting times and local pathways vary across the UK.

If you are unsure whether your symptoms require medical attention, the NHS 111 service can provide guidance. The charity Allergy UK (allergyuk.org) also offers reliable patient information and a helpline for those living with allergic conditions.

Frequently Asked Questions